New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Check below for free stories on FDX;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
15:53 EDTFDXFedEx pleads not guilty to unlawful drug shipping charges, Bloomberg says
FedEx entered a plea of not guilty to U.S. federal charges that it delivered controlled substances and misbranded drugs for illegal internet pharmacies, according to Bloomberg. FedEx may face a fine alleged to be at least $820M if found guilty, Bloomberg added. Reference Link
08:50 EDTLLYHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information
July 18, 2014
16:20 EDTFDXOn The Fly: Closing Wrap
Subscribe for More Information
09:32 EDTFDXFedEx slips in early trading, levels to watch
Subscribe for More Information
06:33 EDTFDXFedEx says loss from DOJ suit 'could be material' if convicted
Subscribe for More Information
06:30 EDTFDXFedEx says innocent of charges brought by Justice Department
Subscribe for More Information
July 17, 2014
18:54 EDTFDXFedEx says innocent of drug charges, will plead not guilty, Bloomberg reports
18:52 EDTFDXFedEx indicted for its role in distributing controlled substances
Subscribe for More Information
July 16, 2014
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Subscribe for More Information
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
06:18 EDTFDXTNT Express receives Statement of Objections from French Competition Authority
Subscribe for More Information
06:16 EDTFDXFedEx says France investigating anticompetitive behavior
On June 30, FedEx said it received a Statement of Objections from the French Competition Authority addressed to FedEx Express France, formerly known as TATEX, regarding an investigation by the FCA into anticompetitive behavior that is alleged to have occurred primarily in the framework of trade association meetings that included the former general managers of TATEX prior to our acquisition of that company in July 2012. FedEx says that "Given the early stage of this matter, we cannot yet determine the amount or range of potential loss; however, it is reasonably possible that it could be material."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use